US Health Ministry Axes mRNA Vaccine Push Amid Funding Shift
Nearly $500 Million Reallocated as Focus Shifts to “Safer Platforms”
The U.S. Health Ministry is drastically altering its biomedical research strategy, cutting substantial funding for mRNA vaccine development. This significant pivot redirects nearly half a billion dollars away from 22 affected projects, following a thorough review of investments made during the COVID-19 pandemic.
Review Spurs Major Investment Rethink
Health Minister Robert F. Kennedy Jr. announced the discontinuation of specific programs, citing data that suggests these vaccines do not offer robust protection against common upper respiratory infections like COVID-19 and influenza. He stated that the freed-up resources would be redirected towards “safer, broader vaccine platforms.”
“We will stop this program because the data showed that these vaccines would not effectively protect against infections of the upper respiratory tract such as covid and flu.”
—Robert F. Kennedy Jr., US Health Minister
Minister Kennedy Jr. did not present specific scientific evidence to support his assertions regarding the vaccines’ efficacy limitations. Meanwhile, the ministry has already terminated its contract with Moderna concerning the late-stage development of a bird flu vaccine for human use.
Contracts Canceled, Future Projects Scrutinized
Further scaling back includes the rejection or cancellation of several pending tenders. Companies such as Pfizer, Sanofi Pasteur, CSL SEQIRUS, and Gritstone were among those impacted by these decisions. German biotech firm Biontech, a significant player in mRNA technology, is also active in this field.
The U.S. Health Ministry’s Biomedical Research Department has historically supported companies in developing countermeasures for public health crises, providing billions for COVID-19 vaccine development during the pandemic. However, recent findings have prompted a significant strategic realignment.
The Centers for Disease Control and Prevention (CDC) reported that flu vaccines have shown varying effectiveness in recent years, with a 2022-2023 season estimate of around 36% effectiveness against the flu (Source: CDC). This backdrop highlights the ongoing challenges in vaccine development against rapidly evolving viruses.
Moderna Contract Terminated, Other Firms Affected
The decision to end the Moderna contract is a key element of this funding reallocation. Numerous other tenders from major pharmaceutical and biotechnology companies are also under review or have been canceled as the ministry reshapes its research priorities.
The Ministry aims to support a more diverse range of vaccine technologies, potentially investing in platforms that offer broader protection or target a wider array of pathogens. This strategic shift reflects a desire for more resilient and adaptable public health interventions.